National Vision EYE
- Market cap
- $1.4B
- PE
- 28.1×
- 8y median 52.7×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.7×
- EV/EBIT
- 17.8×
- Revenue, 12 months
- $2B
- +8% on a year ago
- Net margin
- 2.5%
- Free cash flow yield
- 3.6%
National Vision trades at 28.1× trailing earnings, cheaper than 86% of the last ten years. Revenue was $2B over the last twelve months, up 8% on a year earlier with a 2% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $438.8M−12% | $421M−10% | $482.8M+4% | $451.7M+5% | $451.5M+3% | $437.3M+4% | $510.3M+6% | $486.4M+8% | $487.3M+8% | $503.4M+15% | $543.9M+7% | $498.8M+3% | |
| Cost of revenue | $183.8M−21% | $184.4M−17% | $195.5M+5% | $193.6M+7% | $189.9M+3% | $185M+0% | $205.2M+5% | $200.4M+4% | $203.2M+7% | $210.7M+14% | $219.1M+7% | $208.4M+4% |
| Gross profit | $255M−4% | $236.6M−4% | $287.2M+3% | $258.2M+3% | $261.6M+3% | $252.3M+7% | $305.1M+6% | $286.1M+11% | $284.1M+9% | $292.7M+16% | $324.7M+6% | $290.4M+2% |
| SG&A | $227.5M+1% | $248.3M+6% | $240.1M+3% | $231.4M+4% | $234M+3% | $233.1M−6% | $255.5M+6% | $247.2M+7% | $252.3M+8% | $261.2M+12% | $256.1M+0% | $243.4M−2% |
| $3.5M−77% | −$12.4M+27% | $23.4M−16% | $591K−89% | −$8.8M | −$25.6M+106% | $26.1M+12% | $16.4M+2683% | $9.6M | $6.6M | $45.2M+73% | $21.3M+30% | |
| Interest expense | $3.7M | $3.9M | $4.3M | $3.2M | $4.1M+10% | $4.6M+18% | $4.6M+7% | $4.2M+32% | $4.1M+0% | $4.2M−8% | $2.8M−38% | $3.3M−21% |
| Pre-tax income | −$175K | −$16.9M+37% | $19.2M−21% | −$2.6M | −$12.1M+6797% | −$30.2M+78% | $21.6M+12% | $12.2M | $5.5M | $2.4M | $42.4M+97% | $18M+47% |
| $191K−97% | −$2.2M−30% | $7.4M−10% | −$1.6M | −$3.6M | −$758K−65% | $7.4M−1% | $3.5M | $2.1M | −$929K+23% | $11.2M+52% | $5.5M+58% | |
| Net income | −$73.8M | −$16M+73% | $11.7M−36% | −$3.1M | −$8.5M−89% | −$28.6M+79% | $14.2M+21% | $8.7M | $3.4M | $3.3M | $31.2M+120% | $12.4M+42% |
| −$0.94 | −$0.20+67% | $0.15−25% | −$0.04 | −$0.11−88% | −$0.36+80% | $0.18+20% | $0.11 | $0.04 | $0.04 | $0.38+111% | $0.15+36% | |
| 78.2M−1% | 78.3M−1% | 78.8M−14% | 78.6M+0% | 78.7M+1% | 78.8M+1% | 79.3M+1% | 80.1M+2% | 81.2M+3% | 81.7M+4% | 81.5M+3% | 80.6M+1% |
Gross profit: 40 periods, Q3 FY16 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 11 periods, Q4 FY16 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY16 and Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY20 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest National Vision's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| LMATLemaitre Vascular | $1.9B | 28.5× | 42.0× | 7.1× | +12% | 25.0% | |
| INSPInspire Medical Systems | $1.9B | 14.5× | 56.6× | 2.2× | −0% | 15.0% | |
| UFPTUFP Technologies | $2.2B | 30.6× | 25.6× | 3.5× | +7% | 11.4% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| WRBYWarby Parker | $2.9B | 341× | 359× | 3.2× | +11% | 0.8% | |
| Peer median | $1.3B | 34.8× | 41.7× | 2.7× | +9% | 7.7% |
More on National Vision
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .